Deaths in trials should always be reported

    loading  Checking for direct PDF access through Ovid

Abstract

In Novo Nordisk's internal reports of trials of the diabetes drug repaglinide, Jeppe Schroll finds deaths that were not reported in published trials, potentially underplaying harms in subsequent analyses

Related Topics

    loading  Loading Related Articles